If You Invested in Emmaus Life Scie (EMMA)

Emmaus Life Sciences, Inc. (OTCQB: EMMA) is a commercial-stage biopharmaceutical company focused on the discovery, development, marketing, and sale of treatments and therapies, including those for rare and orphan diseases. The company is repeatedly described in its public communications as a leader in the treatment of sickle cell disease and is based in Torrance, California.

Emmaus’ business centers on Endari®, its prescription-grade L-glutamine oral powder. According to the company, Endari is approved to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Endari received U.S. Food and Drug Administration (FDA) approval in July 2017 for treating sickle cell disease in this patient population. Emmaus reports that Endari is approved for marketing in the United States, Israel, Kuwait, Qatar, the United Arab Emirates, Bahrain, and Oman, and is available on a named patient or early access basis in France, the Netherlands, and the Kingdom of Saudi Arabia, where the company’s application for marketing authorization is awaiting final action by the Saudi Food & Drug Authority.

Business focus and therapeutic area

Emmaus describes itself as a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing, and sale of innovative treatments and therapies. In multiple press releases, the company emphasizes its focus on sickle cell disease and characterizes itself as a leader in this therapeutic area. Sickle cell disease is highlighted by Emmaus as a serious inherited blood disorder affecting approximately 100,000 people in the United States and millions more globally, with significant impacts on red blood cell function, blood flow, pain, organ damage, and life expectancy.

The company positions Endari as a therapy indicated to reduce the acute complications of sickle cell disease in adults and children aged five years and older. Emmaus also notes that it works in therapeutic areas that include rare and orphan diseases, which aligns with the nature of sickle cell disease as described in its communications.

Geographic reach of Endari®

According to Emmaus’ public disclosures, Endari is approved for marketing in multiple countries and regions. The company states that Endari is approved in the United States, Israel, Kuwait, Qatar, the United Arab Emirates, Bahrain, and Oman. It further notes that Endari is available on a named patient or early access basis in France, the Netherlands, and the Kingdom of Saudi Arabia, pending final action on a marketing authorization application in Saudi Arabia.

Emmaus has also reported that Endari has been afforded market exclusivity in the Kingdom of Saudi Arabia by the National Unified Procurement Company (NUPCO) for an initial period, with the potential for an extended exclusivity period if Endari is approved for marketing in that country. The company highlights this as an opportunity in what it describes as a large addressable market of affected patients within the Saudi healthcare system.

Commercial model and strategic agreements

Emmaus identifies itself as a commercial-stage company, meaning it generates revenue from the sale of Endari. Its periodic financial results press releases discuss net revenues from Endari sales in the United States and in regions such as the Middle East and North Africa (MENA). The company has also discussed the impact of inventory availability and competition from generic L-glutamine oral powder on its revenues and operating results.

On December 24, 2025, Emmaus entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (NIT), as disclosed in a Form 8-K filing and a related press release. Under this agreement, Emmaus granted NIT an exclusive license to all rights to market, sell, and distribute Endari and any generic equivalents in sickle cell disease in the United States, its territories, and Canada, in exchange for an upfront payment and a royalty on NIT’s product sales. The Form 8-K explains that the effective date of this agreement is subject to NIT obtaining necessary regulatory approvals and licensing and to other specified conditions.

In connection with the effective date of this license, Emmaus and NIT are expected to enter into an exclusive supply arrangement under which Emmaus will agree to supply Endari to NIT, and NIT will, subject to certain exceptions, purchase its requirements for the product from Emmaus at a price based on Emmaus’ cost of production plus an agreed margin. Emmaus retains all rights to Endari outside the licensed field and territory, and each party may make improvements to the products, with cross-rights to such improvements as described in the filing.

Regulatory and product information

Emmaus provides detailed information about Endari’s indication and safety profile in its communications. Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. The company notes that the most common adverse reactions (with incidence greater than 10 percent in clinical studies) include constipation, nausea, headache, abdominal pain, cough, pain in extremities, back pain, and chest pain. Adverse reactions leading to treatment discontinuation in clinical studies included single cases of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash. Emmaus states that the safety and efficacy of Endari in pediatric patients younger than five years of age have not been established.

In June 2025, Emmaus announced that it had received FDA approval for changes to the Endari label based on additional post-marketing pharmacokinetic study data. The company reported that the additional information provides a more comprehensive characterization of Endari, including confirmation of dosing by body weight, no unwanted accumulation with twice-daily dosing, and the ability to administer Endari with or without food. Emmaus notes that Endari is approved in the U.S. and elsewhere to reduce acute complications of sickle cell disease in adults and pediatric patients five years and older.

Financial reporting and trading venue

Emmaus files periodic financial reports and issues press releases summarizing its financial condition and results of operations. These releases discuss net revenues, operating expenses, income or loss from operations, other income or expense, net income or loss, and liquidity and capital resources. The company has reported factors affecting its results, such as inventory shortages, competition from generic L-glutamine oral powder, changes in operating expenses, gains or losses related to debt restructuring, and changes in the fair value of derivative liabilities.

Emmaus states in its press releases that its common stock trades on the OTCQB or OTC Markets under the symbol EMMA. An 8-K filing notes that the company has no securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934, indicating that its shares are not listed on a national securities exchange.

Corporate and capital structure developments

Emmaus has reported various corporate developments through its SEC filings. For example, in an 8-K dated December 17, 2025, the company disclosed an Exchange Agreement under which it agreed to issue shares of common stock and a convertible promissory note in exchange for the cancellation and satisfaction of an outstanding convertible promissory note. The filing describes the interest rate, conversion price, and adjustment mechanisms for the new note and indicates that the principal amount is due on demand. The company also reports that the exchange was conducted without additional consideration and relied on a registration exemption under Section 3(a)(9) of the Securities Act of 1933.

In another 8-K, Emmaus disclosed the resignation of a director, effective at a specified date. The company also files 8-Ks to furnish press releases regarding its quarterly financial results, as indicated in the November 14, 2025 filing referencing a press release covering the three months ended September 30, 2025.

Sickle cell disease context as described by Emmaus

Emmaus’ communications include background information on sickle cell disease. The company notes that there are approximately 100,000 people living with sickle cell disease in the United States and millions more globally. It states that the sickle gene is found in every ethnic group and provides estimates of disease incidence among African Americans and Hispanic Americans in the United States. Emmaus explains that the genetic mutation responsible for sickle cell disease causes red blood cells to distort into a sickle shape, which reduces their ability to transport oxygen, leads to rapid breakdown of red blood cells, and causes them to become sticky and prone to clumping. According to the company, this can result in reduced blood flow, incapacitating pain, tissue and organ damage, and early death.

Risk and forward-looking statements

Emmaus’ financial and corporate press releases include forward-looking statements and refer readers to its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q for a discussion of risks and uncertainties. In one release, the company notes that these risks include doubt about its ability to continue as a going concern, among other factors. The company emphasizes that actual results may differ materially from forward-looking statements and that such statements speak only as of the date made.